Read previous post:
Theratechnologies CEO John-Michel T. Huss. The company today announced that Health Canada is now reviewing tesamorelin, and expects to receive a decision within 150 days.
Theratechnologies rises after tesamorelin update

Shares of Theratechnologies (TSX:TH) rose in Toronto on Wednesday after providing investors with an update on the marketing authorization progress...